Shares of Dova Pharmaceuticals Inc (NASDAQ:DOVA) were up 7.9% during mid-day trading on Thursday . The stock traded as high as $9.58 and last traded at $9.37. Approximately 217,482 shares were traded during mid-day trading, an increase of 33% from the average daily volume of 163,493 shares. The stock had previously closed at $8.68.
Several analysts recently issued reports on DOVA shares. BidaskClub upgraded Dova Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, March 21st. Wedbush started coverage on Dova Pharmaceuticals in a research note on Wednesday, May 22nd. They issued an “outperform” rating and a $19.00 price target for the company. Finally, HC Wainwright set a $18.00 price target on Dova Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, March 5th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $28.25.
The firm has a market cap of $261.13 million, a price-to-earnings ratio of -3.56 and a beta of 1.80. The company has a debt-to-equity ratio of 0.20, a current ratio of 4.46 and a quick ratio of 4.27.
Hedge funds and other institutional investors have recently made changes to their positions in the business. PNC Financial Services Group Inc. raised its holdings in Dova Pharmaceuticals by 14,705.9% in the 4th quarter. PNC Financial Services Group Inc. now owns 5,034 shares of the company’s stock valued at $38,000 after acquiring an additional 5,000 shares in the last quarter. DekaBank Deutsche Girozentrale raised its holdings in Dova Pharmaceuticals by 22.0% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 13,300 shares of the company’s stock valued at $336,000 after acquiring an additional 2,400 shares in the last quarter. Rhumbline Advisers raised its holdings in Dova Pharmaceuticals by 46.1% in the 4th quarter. Rhumbline Advisers now owns 15,343 shares of the company’s stock valued at $116,000 after acquiring an additional 4,843 shares in the last quarter. State of Wisconsin Investment Board raised its holdings in Dova Pharmaceuticals by 29.3% in the 1st quarter. State of Wisconsin Investment Board now owns 15,900 shares of the company’s stock valued at $141,000 after acquiring an additional 3,600 shares in the last quarter. Finally, Two Sigma Investments LP acquired a new position in Dova Pharmaceuticals in the 4th quarter valued at $136,000. 30.18% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This story was published by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/4372384/dova-pharmaceuticals-nasdaqdova-trading-up-7-9.html.
About Dova Pharmaceuticals (NASDAQ:DOVA)
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.
Recommended Story: How is the LIBOR rate calculated?
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.